Loading data for AMLX — first visit, this takes a few seconds.

Amylyx Pharmaceuticals, Inc. (AMLX)

NasdaqGS: AMLX · 即時價格 · USD

34.10

+0.14 (0.41%)

收盤價： Sep 11, 2026, 3:59 PM

31.72

+0.32%

盤後: 7:47 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

0.41% (1D)

買價	24.16
市值	3.52B
營收 (ttm)	n/a
淨利（ttm）	-152M
	-0.12
	-1.41
	n/a
	-27.38
P/B (ttm)	14.72
P/S (ttm)	0.00
財報日期	Nov 5, 2026

賣價	42.99
成交量	885,518
20 日平均成交量	2,474,669
開盤價	33.38
前收盤價	33.96
當日區間	33.38 - 34.24
52 週範圍	10.37 - 41.14
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also devel...

類股 Healthcare

IPO 日期 Jan 7, 2022

員工 136

證券交易所 NasdaqGS

股票代號 AMLX

網站 https://amylyx.com

完整的公司簡介

財務表現

Amylyx Pharmaceuticals 在 2025 年的營收為 0，較前一年的 87.37M 減少 -100%。淨利為 -144.74M，較前期減少 -52.03%。

財務報表

財報驚奇

Amylyx Pharmaceuticals 已於 Aug 6, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.39 低於預期 -0.03, 年增 15.22% 成長.

下次財報發布

Amylyx Pharmaceuticals, Inc. 的下次財報預計於 Nov 5, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

1 週前 · Motley Fool

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx looks promising, but a pullback would improve the opportunity.

1 週前 · Motley Fool

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

2 週前 · Simply Wall St.

Oracle Stock And 2 High Growth Picks Backed By Rising Credit Demand

Eurozone private sector credit growth is gaining pace, which points to households and businesses feeling more confident about borrowing for spending and investment. That kind of backdrop can support c...

2 週前 · Simply Wall St.

Oracle Stock And 2 Growth Picks With Strong Earnings Potential

Germany’s Ifo index has reached a one year high, which hints at a more confident backdrop for companies planning to grow earnings rather than just defend margins. That creates an interesting setting f...

3 週前 · Motley Fool

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

The biotech delivered excellent news from the laboratory.

第 1 頁，共 2 頁

Amylyx Pharmaceuticals, Inc. (AMLX)